Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia.

Lemos EV, de la Hoz FP, Alvis N, Einarson TR, Quevedo E, Castañeda C, Leon Y, Amado C, Cañon O, Kawai K.

Clin Microbiol Infect. 2014 Feb;20(2):174-80. doi: 10.1111/1469-0691.12251. Epub 2013 May 13.

2.

The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection.

de Gouvêa EF, Martins IS, Halpern M, Ferreira AL, Basto ST, Gonçalves RT, Moreira BM, Santoro-Lopes G.

BMC Infect Dis. 2012 Dec 13;12:351. doi: 10.1186/1471-2334-12-351.

3.

Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.

Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH.

Antimicrob Agents Chemother. 2011 Oct;55(10):4844-9. doi: 10.1128/AAC.01728-10. Epub 2011 Aug 8.

4.

Epidemiology and impact of imipenem resistance in Acinetobacter baumannii.

Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M.

Infect Control Hosp Epidemiol. 2009 Dec;30(12):1186-92. doi: 10.1086/648450.

PMID:
19860563
5.

Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.

Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP, Ti-Yin, Chen TL, Fung CP.

J Microbiol Immunol Infect. 2012 Oct;45(5):356-62. doi: 10.1016/j.jmii.2011.12.009. Epub 2012 May 9.

6.

[Acinetobacter baumannii - related mortality in intensive care units in Colombia].

Lemos EV, De la Hoz Restrepo F, Alvis N, Quevedo E, Cañon O, León Y.

Rev Panam Salud Publica. 2011 Oct;30(4):287-94. Spanish.

7.

Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit.

Prates CG, Martins AF, Superti SV, Lopes FS, Ramos F, Cantarelli VV, Zavascki AP.

Epidemiol Infect. 2011 Mar;139(3):411-8. doi: 10.1017/S0950268810001238. Epub 2010 Jun 1.

PMID:
20513254
8.

Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.

Zheng YL, Wan YF, Zhou LY, Ye ML, Liu S, Xu CQ, He YQ, Chen JH.

Am J Infect Control. 2013 Jul;41(7):e59-63. doi: 10.1016/j.ajic.2013.01.006. Epub 2013 Mar 21.

PMID:
23523521
9.

Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates.

Kopterides P, Koletsi PK, Michalopoulos A, Falagas ME.

Int J Antimicrob Agents. 2007 Nov;30(5):409-14. Epub 2007 Sep 11.

PMID:
17851052
10.

A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.

Nutman A, Glick R, Temkin E, Hoshen M, Edgar R, Braun T, Carmeli Y.

Clin Microbiol Infect. 2014 Dec;20(12):O1028-34. doi: 10.1111/1469-0691.12716. Epub 2014 Aug 11.

11.

Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia.

Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, Ko WC.

Infect Control Hosp Epidemiol. 2007 Jun;28(6):713-9. Epub 2007 May 14.

PMID:
17520546
12.

Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital.

Aydemir H, Celebi G, Piskin N, Oztoprak N, Keskin AS, Aktas E, Sumbuloglu V, Akduman D.

Jpn J Infect Dis. 2012;65(1):66-71.

13.

Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections.

Song JY, Cheong HJ, Choi WS, Heo JY, Noh JY, Kim WJ.

J Med Microbiol. 2011 May;60(Pt 5):605-11. doi: 10.1099/jmm.0.029439-0. Epub 2011 Jan 13.

PMID:
21233298
14.

Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific.

Le Hello S, Falcot V, Lacassin F, Mikulski M, Baumann F.

Scand J Infect Dis. 2010 Dec;42(11-12):821-6. doi: 10.3109/00365548.2010.496087. Epub 2010 Jun 21.

PMID:
20560868
15.

Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.

Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW.

J Korean Med Sci. 2012 May;27(5):471-5. doi: 10.3346/jkms.2012.27.5.471. Epub 2012 Apr 25.

16.

Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal intensive care unit: a case-case-control study.

Thatrimontrichai A, Apisarnthanarak A, Chanvitan P, Janjindamai W, Dissaneevate S, Maneenil G.

Pediatr Infect Dis J. 2013 Feb;32(2):140-5. doi: 10.1097/INF.0b013e318270b108.

PMID:
22935872
17.

Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.

Munoz-Price LS, Zembower T, Penugonda S, Schreckenberger P, Lavin MA, Welbel S, Vais D, Baig M, Mohapatra S, Quinn JP, Weinstein RA.

Infect Control Hosp Epidemiol. 2010 Oct;31(10):1057-62. doi: 10.1086/656247.

PMID:
20715975
18.

Outbreak of resistant Acinetobacter baumannii- measures and proposal for prevention and control.

Romanelli RM, Jesus LA, Clemente WT, Lima SS, Rezende EM, Coutinho RL, Moreira RL, Neves FA, Brás Nde J.

Braz J Infect Dis. 2009 Oct;13(5):341-7. doi: 10.1590/S1413-86702009000500005.

19.

Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intensive care unit, Delhi, India.

Kumar A, Randhawa VS, Nirupam N, Rai Y, Saili A.

J Infect Dev Ctries. 2014 Aug 13;8(8):1049-54. doi: 10.3855/jidc.4248.

20.

Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.

Anunnatsiri S, Tonsawan P.

Southeast Asian J Trop Med Public Health. 2011 May;42(3):693-703.

PMID:
21706949

Supplemental Content

Support Center